Maroussi, Greece – January 30, 2025 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (“we”, “our”, “us”, the “Company” or “Pyxis Tankers”), an international shipping company, announced today key shareholder and chartering updates. The Company has completed its authorized expanded $3.0 million common share repurchase program. Since summer 2023, we have acquired 730,683 common shares in the open market at an average cost of $4.03 per share, excluding commissions. As of January 29, 2025, there were 10,485,865 com ...

RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-20 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock par value $0.001 per share (the "Common Stock"), effective with the opening of trading on Tuesday, February 4, 2025. Glucotrack ...

Initiative Drives Operational Efficiencies and Unlocks New Growth Possibilities for Podcasters and Advertisers LOS ANGELES, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PodcastOne (NASDAQ:PODC), a leading publisher and podcast sales network, announced today that it has moved its existing network of programming to hosting service ART19, the podcast distribution and monetization service that lets customers manage content and ad operations in one place. The move streamlines PodcastOne's hosting capabilities, while drivin ...

CORNELIUS, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus”, “AMOD”, or the “Company”), in a statement today, through Alpha Modus CEO William Alessi, emphasized the company's strong fundamentals, ongoing growth strategy, and commitment to delivering value to shareholders amidst what he described as "uninformed speculation" by certain market participants. "The recent sell side activity targeting AMOD stock appears to be driven by misconceptions and a lack of un ...

Hamilton, Bermuda and Paris, France, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The RoyaLand Company Ltd. (OTCQB: RLNDF) (“RoyaLand” or the “Company”), a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land, today announced the introduction of a mobile companion application for TheRoyal.Land. RoyaLand’s companion app is designed to bridge the gap between digital entertainment and cultural education, inviting players to step into real loc ...

COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs. MSD Global Health Innovation Fund, a corporate ventur ...

CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 1 ...

Boston (January 30, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, has filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC") regarding its agreement in principle with the SEC staff to resolve the previously disclosed SEC investigation. The settlement relates to the Company's disclosures, ...

Groundbreaking research to evaluate the effects of EL-32, alone and in combination with semaglutide, on glycemic control and body composition in diet-induced obese mice.EL-32 is an engineered probiotic expressing dual myostatin & activin-A, focusing on two clinically validated targets that play an important role in regulating muscle. NEWPORT BEACH, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB), today announced that its subsid ...

FREMONT, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ:ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that it is expanding in Southeast Asia by entering the solar markets in Vietnam and Malaysia. Enphase is now shipping IQ8P™ Microinverters, with peak output AC power of 480 W, for residential and commercial applications in Vietnam and Malaysia to support newer high-powered solar modules. En ...